NasdaqGS - Nasdaq Real Time Price USD

Insulet Corporation (PODD)

149.68 -2.82 (-1.85%)
At close: October 30 at 4:00:00 PM EDT
149.68 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade Insulet on Coinbase
Chart Range Bar
Loading chart for PODD

What's happening with PODD?

58m ago
Powered by Yahoo Scout

Insulet is scheduled to report fiscal third-quarter 2026 results before the market opens on November 4. Analysts expect higher earnings and revenue, while investors remain focused on Type 2 customer retention, competition, GLP-1 effects, and the Omnipod platform’s growth. The company recently launched Omnipod Discover in the United States.

Powered by Yahoo Scout
  • Previous Close 152.50
  • Open 154.60
  • Bid 141.08 x 200
  • Ask 162.03 x 200
  • Day's Range 149.48 - 154.60
  • 52 Week Range 126.40 - 354.88
  • Volume 1,090,196
  • Avg. Volume 1,693,031
  • Market Cap (intraday) 10.381B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) 28.03
  • EPS (TTM) 5.34
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 167.17
  • Morningstar Rating
    Rating available with Stock Picks access

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

www.insulet.com

5,400

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PODD
47.34%
S&P 500 (^GSPC)
10.73%

1-Year Return

PODD
52.02%
S&P 500 (^GSPC)
11.11%

3-Year Return

PODD
14.47%
S&P 500 (^GSPC)
81.91%

5-Year Return

PODD
51.72%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 801.7M
Earnings 95M
Profit Margin 11.85%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
12.0%
12.2%
12.4%
12.6%
12.8%
 

Analyst Insights

View More

Top Analyst

Jefferies
62/100
Latest Rating
Buy
 

Analyst Price Targets

143.00
167.17 Average
149.68 Current
215.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/12/2026
Analyst Jefferies
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 275 -> 190
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    10.39B

  • Enterprise Value

    10.80B

  • Trailing P/E

    28.05

  • Forward P/E

    19.38

  • PEG Ratio (current)

    0.28

  • Price/Sales (ttm)

    3.51

  • Price/Book (mrq)

    7.31

  • Enterprise Value/Revenue

    3.54

  • Enterprise Value/EBITDA

    17.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.29%

  • Return on Assets (ttm)

    9.71%

  • Return on Equity (ttm)

    26.02%

  • Revenue (ttm)

    3.05B

  • Net Income Avi to Common (ttm)

    375.3M

  • Diluted EPS (ttm)

    5.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    534.9M

  • Total Debt/Equity (mrq)

    71.40%

  • Levered Free Cash Flow (ttm)

    236.9M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

149.68 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Raising target price to $165.00

    INSULET CORP has an Investment Rating of BUY; a target price of $165.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Raising target price to $157.00

    INSULET CORP has an Investment Rating of BUY; a target price of $157.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Raising target price to $152.00

    INSULET CORP has an Investment Rating of BUY; a target price of $152.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Raising target price to $148.00

    INSULET CORP has an Investment Rating of BUY; a target price of $148.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

     

People Also Watch